The EMPA-KIDNEY trial has demonstrated that empagliflozin reduces the risk of kidney disease progression or death from cardiovascular disease by 28% in people with chronic kidney disease.

Oxford Population Health are a world-leading research institute that investigates the causes and prevention of diseases.

Read more: [ Ссылка ]

свернуть